TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04791202
Drug: Methylprednisolone Acetate 40 MG/ML
Normalized name: methylprednisolone acetate 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm descriptions
Study: NCT06163352
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
Study: NCT05238155
Drug: antimetabolite
Normalized name: Antimetabolite
Approvals — FDA: no, EMA: no, PMDA: no
Description: When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
Study: NCT05411874
Drug: HD-DXM
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg po qd for 4days
Study: NCT06160622
Drug: Leritrelvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05199441
Drug: Control group placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group takes 1,500 mg/day of placebo for 8 weeks.
Study: NCT04488003
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
Study: NCT04927338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
Study: NCT05083260
Drug: NE3107
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
Study: NCT05083260
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsule containing only common excipients for oral formulations
Study: NCT05150587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT05377944
Drug: BAT2306
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/1 ml/injection (2 injections/visit)
Study: NCT06178757
Drug: EOIB
Normalized name: Ethinyl Estradiol and Norgestimate
Approvals — FDA: no, EMA: no, PMDA: no
Description: As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
Study: NCT05197075
Drug: DRV/COBI FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/COBI FDC tablet dispersed in water will be administered orally.
Study: NCT04876651
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
Study: NCT05620017
Drug: BAT8008 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
Study: NCT05098327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills containing cellulose 1 pill daily will be given for 12 weeks
Study: NCT05431634
Drug: Experimental drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ESK-001
Study: NCT06271564
Drug: Magnetite ZnO Composite Nanoparticles
Normalized name: magnesite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
Study: NCT06271564
Drug: Topical Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
Study: NCT06146413
Drug: Double trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
Study: NCT06146413
Drug: HCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG ( 10000 IU) is administered 36 h before ovum pick-up
Study: NCT04768868
Drug: IMP7068
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
Study: NCT05154240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05219968
Drug: LYR-210
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR-210 drug matrix (mometasone furoate)
Study: NCT05219968
Drug: Sham procedure control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure control
Study: NCT05738460
Drug: antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
Study: NCT05582096
Drug: LY3457263
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05582096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05923086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration before major meal
Study: NCT06223841
Drug: IAP0971
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAP0971 should be subcutaneous injected，q3w
Study: NCT05797883
Drug: FOLFOX/FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
Study: NCT05706636
Drug: oral mini pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg / week oral dexamethasone
Study: NCT05706636
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical fluticasone cream for body lesions and topical tacrolimus for face lesions
Study: NCT04732247
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal treatment with placebo via nasal spray
Study: NCT05490940
Drug: Tisseel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc).
Study: NCT04963946
Drug: ACA Continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuation of acalabrutinib at the same dose
Study: NCT04031573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via the enteral route, every 12 hours.
Study: NCT04661475
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
Study: NCT05710198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops containing placebo matching product
Study: NCT04703257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
Study: NCT00002093
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05763082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04826497
Drug: Placebo（normal saline）
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
Study: NCT06177171
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Orally
Study: NCT06031597
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
Study: NCT06031597
Drug: Immunotherapeutic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
Study: NCT05730972
Drug: Routine palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
Study: NCT04996199
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
Study: NCT06577766
Drug: NNC0638-0355
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
Study: NCT06577766
Drug: Placebo (NNC0638-0355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
Study: NCT04626973
Drug: Statin monotherapy (rosuvastatin or atorvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
Study: NCT04626973
Drug: Statin monotherapy (rosuvastatin or atorvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
Study: NCT04959500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Study: NCT00000636
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04583462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
Study: NCT05598177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will pump saline without dexmedetomidine at the same speed as group D.
Study: NCT05253911
Drug: TUKYSA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
Study: NCT05907486
Drug: N-acetyl-cysteine
Normalized name: Dendrimer N-acetyl-cysteine
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45
Study: NCT05907486
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8g/m2, day -4 to day -3, intravenously
Study: NCT06014736
Drug: XJ101 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
Study: NCT06014736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only excipients.
Study: NCT06084676
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
Study: NCT04826328
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single peripheral nerve injection
Study: NCT06031961
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
Study: NCT06351644
Drug: ON 123300
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study.
Study: NCT06618105
Drug: Test Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo of T inhalation aerosol
Study: NCT06618105
Drug: Reference Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo of R inhalation aerosol
Study: NCT06623201
Drug: aminolevulinic acid HCL (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
Study: NCT06625840
Drug: MK-1167
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT06625840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT06625541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06624436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
Study: NCT05808335
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)
Study: NCT05503693
Drug: AP303 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 tablet
Study: NCT05503693
Drug: AP303 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 tablet
Study: NCT05503693
Drug: AP303 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 tablet
Study: NCT05503693
Drug: Placebo 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05503693
Drug: Placebo 600 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05350124
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vitamin C (200 mg) capsule
Study: NCT05350124
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two pills only
Study: NCT06019013
Drug: QLF3108
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLF3108 will be administered independent of body weight.
Study: NCT05241054
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 1 microgram.kg
Study: NCT05582590
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
Study: NCT05865925
Drug: LY010616
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
Study: NCT05554926
Drug: AEF0117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
Study: NCT06058390
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered.
Study: NCT06319235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
Study: NCT04797325
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet prednisolone plus infliximab in severe cases.
Study: NCT04975100
Drug: Placebo and SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
Study: NCT06465992
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
Study: NCT00111124
Drug: Enbrel®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04166110
Drug: Predetermined treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
Study: NCT04166110
Drug: Variable treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment.
Study: NCT05370898
Drug: Caltrate D
Normalized name: Caltrate Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
Study: NCT05370898
Drug: Chinese medicine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Study: NCT05370898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Study: NCT04764201
Drug: HIP2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04764201
Drug: HGP2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT05822843
Drug: ESG206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion